Mounjaro 10mg Kwikpen

• Mounjaro is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Clinical Usage:
• Second-line therapy when metformin is contraindicated or insufficient
• Combination therapy with other antidiabetic medications
• Alternative to insulin therapy in appropriate patients
• Management of patients requiring both glycemic control and weight reduction
• Mounjaro should be taken as and when prescribed by a doctor for:
• Adults (≥18 years) with confirmed type 2 diabetes when metformin, dietary modifications, and exercise fail to achieve desired blood sugar control.
• Inadequate blood sugar management despite lifestyle modifications
• HbA1c ≥7% or as clinically appropriate
• Patients requiring weight management alongside diabetes management, depending on the BMI and associated comorbidities

• Administering Maounjaro is contraindicated in the following situations or conditions:
• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Hypersensitivity to Tirzepatide or any of its components
• Previous serious allergic reactions to GLP-1 receptor agonists

• Abdominal pain
• Constipation
• Indigestion
• Nausea
• Diarrhea
• Vomiting
• Other Common Effects:
• Decreased appetite
• Hypoglycemia (drop in blood sugar below 70 mg/dL)
• Injection site reactions

Other General Warnings

• You have a history of pancreatitis.
• You experience severe abdominal pain, nausea, or vomiting, which could indicate pancreatitis.
• You have type 2 diabetes and are taking insulin or a sulfonylurea, as you may be at an increased risk of hypoglycemia.
• You experience frequent nausea, vomiting, or diarrhoea, which may lead to dehydration and kidney issues.
• You have kidney disease, have had a kidney transplant, or have liver disease.
• You are elderly, especially if you are over 85 years old, as there is limited data on safety in this age group.
• You have a disease of the gallbladder or experience symptoms such as abdominal pain, yellowing of the skin or eyes (jaundice), clay-coloured stools, and fever.
• You have severe gastrointestinal disease, including gastroparesis (delayed emptying of the stomach due to reduced movement), as this injection has not been studied in such patients.
• You have eye problems, such as diabetic retinopathy or diabetic macular oedema, as this injection should be used cautiously in these conditions.
• You are scheduled for a procedure requiring general anaesthesia or deep sedation, as there is an increased risk of pulmonary aspiration.
• You notice any unusual changes in your vision while using this injection.

• Before using your Mounjaro 10mg KwikPen, allow it to reach room temperature. Always check the vial label to confirm you have the correct medicine and dose, and ensure it has not expired. Examine the pen carefully to make sure it's not damaged. The medicine inside should be clear to slightly yellow in colour, not frozen or cloudy, and free of any particles.
• If anything appears unusual, do not use the vial and contact your healthcare provider immediately.
• Wash your hands thoroughly with soap and water. Choose your injection site on your thigh, upper arm, or stomach area.
• Rotate injection sites to prevent lipodystrophy.
• You may administer an injection of Mounjaro and insulin in the same body area (e.g., the abdomen), but not directly adjacent to each other.
• Administer on the same day each week.
• Can be taken with or without food.
• Store in a refrigerator (2°C to 8°C) until use.
• Do not reuse pens or share them with others.

• Store Mounjaro 10mg KwikPen in a refrigerator at a temperature between 2°C to 8°C.
• If necessary, each single-dose pen or vial can be stored unrefrigerated at temperatures not exceeding 30 °C for up to 21 days.
• Do not freeze. Do not use if frozen.
• Store it in the original carton to protect it from light.

• To help keep your blood sugar levels steady, take Mounjaro 10mg KwikPen on the same day each week. Setting a reminder can help you stay on track.
• Rotate your injection sites (such as the abdomen, thigh, or upper arm) weekly to prevent skin irritation, bruising, or lumps.
• Regularly check your blood glucose to monitor for signs of hypoglycemia, especially if you are on other diabetes medications.
• Eat small, frequent, and balanced meals, and avoid greasy or heavy foods to minimise nausea. Make sure to stay hydrated by drinking plenty of water, especially if you experience nausea, vomiting, or diarrhoea.
• Be aware of serious side effects such as intense stomach pain, signs of pancreatitis (like pain radiating to the back with nausea or fever), or allergic reactions. Contact your doctor immediately if any of these occur.
• Mounjaro 10mg KwikPen may interfere with oral contraceptives. To prevent unintended pregnancy, use a backup birth control method (such as condoms), an intrauterine device (IUD) or switch to a non-oral contraceptive for four weeks after starting treatment and for four weeks after any dose increase.
• Inform your doctor or surgeon that you’re using Mounjaro 10mg KwikPen if you have surgery scheduled, as it may slow down how your stomach empties and increase the risk of complications during anaesthesia.
• Mounjaro 10mg KwikPen is not recommended for patients under 18 years of age.
• Older adults often experience physiological changes that can affect how medications are processed. While the efficacy of this product remains consistent in the elderly, some caution is still necessary.

Overdose

Missed a Dose

How Does It Work?

• Mounjaro differs from other diabetes and weight-loss medications in that it targets two hormone pathways simultaneously.
• While most treatments activate only one receptor, Mounjaro simultaneously activates both the GIP and GLP-1 receptors, providing a more comprehensive approach to blood sugar control and weight management.
• By activating the GIP Receptor pathway, Tirzepatide preserves insulin-producing pancreatic cells while acting on the brain's appetite control centres. This helps naturally reduce food cravings and portion sizes.
• Also, activating the GLP-1 receptor increases insulin sensitivity & secretion, slows gastric emptying, and reduces liver glucose production.
• This dual activation produces a synergistic therapeutic effect that exceeds the sum of individual receptor activations, improving blood glucose control and supporting weight loss.

Interactions with other medicines

• Taking oral medications with a narrow therapeutic index, such as warfarin or digoxin, may be affected by tirzepatide, as it can alter their absorption.
• Using medications that require a rapid onset of action might be problematic since tirzepatide may delay their effects.
• Relying on oral contraceptives may be risky, as tirzepatide could reduce their effectiveness. It is advisable to consider switching to a non-oral contraceptive method or to use additional protection for four weeks after starting tirzepatide or increasing its dose.
• Having obesity or being overweight while using oral contraceptives may be concerning since tirzepatide can influence their efficacy.
• Frequently taking paracetamol might be impacted by tirzepatide, as it may delay its absorption; however, no dose adjustment is typically necessary.
• Taking oral medications with a narrow therapeutic index, such as warfarin or digoxin, may be affected by tirzepatide, as it can alter their absorption.
• Using medications that require a rapid onset of action might be problematic since tirzepatide may delay their effects.
• Relying on oral contraceptives may be risky, as tirzepatide could reduce their effectiveness. It is advisable to consider switching to a non-oral contraceptive method or to use additional protection for four weeks after starting tirzepatide or increasing its dose.
• Frequent paracetamol use may be affected by tirzepatide, which may delay its absorption; however, no dose adjustment is typically necessary.